Market Overview:

The Global HIV Drugs Market Size Was Valued At USD 30.89 Billion In 2019, And Is Expected To Reach USD 34.54 Billion By 2022, And USD 46.55 By 2030 At A CAGR Of 3.8% During The Forecast Period From 2020 To 2027.

The Human Immunodeficiency Virus is one of the most severe and chronic disease. It is a viral infection which is spread through exposure to HIV-infected blood, semen, breast milk, and other infected substances. According to World Health Organization (WHO), there are around 37.7 million people over the world will be infected with the human immunodeficiency virus in 2020. 

In the US, an estimated 34,800 new HIV infections were reported in 2019. After a period of relative stability, new HIV infections decreased by 8%, from 37,800 in 2015 to 34,800 in 2019. In 2019, 36,801 persons in the US and six dependent areas were diagnosed with HIV, a reduction of 9% from 2015. Diagnosis of the human immunodeficiency virus is not spread constantly among states and regions.

The global HIV drugs market has been steadily growing in recent years, driven by increased awareness and diagnosis of HIV/AIDS, as well as the development of new and more effective treatments. The market is also driven by the increasing availability of antiretroviral therapy (ART) in developing countries, which has helped to extend the lives of millions of people living with HIV.

COVID-19 Impact:

• Global Market to Witness Slow Growth due to Declining Number of New Patient Prescriptions during the COVID-19 Pandemic

The COVID-19 pandemic has caused disruption in the import and export of healthcare products across the globe. The pandemic has negative impact the growth of this market due to the disruption and volatility in the supply of drugs. Furthermore, the decreasing number of new patient prescriptions in the U.S., Europe, and other COVID impacted regions/countries has reduced the demand for antiretroviral and antibiotic products globally.

Most of the companies have reported an adverse impact of the pandemic on the sales of HIV/AIDS drugs. For example, Gilead Sciences Inc., one of the leading antiretroviral drug companies, reported that the sales of its HIV medications had decreased due to the lower sales volume of Truvada. Similarly, Theratechnologies Inc. reported a decrease in the sales of HIV drugs such as Trogarzo in the highly COVID impacted countries, which includes regions such as the European Union due to strict lockdown measures imposed in many European countries.  

Furthermore, ViiV Healthcare has also reported that the sales of HIV drugs have decrease significantly in the second quarter of 2020. However, in the fourth quarter of 2020, the demand for HIV/AIDS medications increased. Overall, this market experienced comparatively slow growth during the pandemic.

Latest Trends:

Some of the trends in the global market include development of antiretroviral therapy as a long-acting suppression (ATLAS) and first long-acting injectable formulations. The new ATLAS regimens are convenient treatment for number of patients and as a result, physician states that level of compliance will improve. The alternative option for existing HIV is the combination of cabotegravir and rilpivirin ,the new injectable formulation has now entered the market and increased the quality of care when compare with prescribed HIV drugs.

Market Dynamics:

Driving Factors:

The growth in the research and development of HIV drugs has led to many drug innovations. Key companies engaged in these investment includes Gilead Sciences, ViiV Healthcare and Boehringer Ingelheim International Gmbh. Increase in the number of product launches HIV drug category will increase the market growth.

Restraining Factors:

Despite of advancements in the research and development, improved scientific understanding about HIV and availability of treatments, there are some restraining factors which are responsible for limiting the market growth. Many peoples who are infected with HIV do not have an access to timely treatment. There is no cure for this infection. According to Joint Nation United Programme on HIV, there is uneven distribution of treatment measures across the globe. In the middle-income and developing countries, people still facing issues with the availability of suitable treatment options. 

Many peoples are unaware of their infection status. According to study of Biomed central Ltd. Europe, it was reported that among 467 participants, one-third of participants who were infected with HIV were unaware of their infection.

Challenges:

• High cost of HIV drugs: The cost of HIV drugs can be a major challenge to access for many patients, particularly in low- and middle-income countries. This can limit the availability and uptake of treatment, leading to poorer health outcomes for affected individuals.
• Adherence to treatment: HIV drugs require strict adherence to a daily regimen, which can be difficult for some patients to maintain. Poor adherence can lead to treatment failure, drug resistance, and disease progression.
• Drug resistance: HIV can develop resistance to certain drugs, making them less effective in managing the virus. This can limit treatment options and require the use of more expensive and less accessible drugs.

Strategic Development:

• In January 2021 - ViiV Healthcare received the U.S. FDA approval for Cabenuva, the first and only complete long-lasting regimen combination drug for HIV treatment.
• In September 2019 - Merck Sharp & Dohme Corp., the subsidiary of Merck & Co., Inc., received the U.S. FDA approval for PIFELTRO and DELSTRIGO combination drugs. These drugs can be used to treat adults with HIV-1.
• In February 2018 - Mylan Inc. announced the launch of Efavirenz tablets in the U.S. Efavirenz tablets are the first generic version of Sustiva. This product is given in combination with other antiretroviral agents for the treatment of type 1 HIV infection in adults and paediatric patients.
• In November 2017 - ViiV Healthcare received the U.S. FDA approval for Juluca in the U.S. Juluca is a single-dose antiretroviral (ART) regimen that suppresses the viral infection.
• July 2021 - Unitaid and Clinton Health Access Initiative Inc. (CHAI) announced a pricing agreement with pharmaceutical company Hetero Lab LTD with an aim to make darunavir to combine with ritonavir (DRV/r) as a second –line therapy for HIV patients living in low and middle income countries for US$ 210 per patient per year.
• March 2021 - Gilead Science and Merck announced a collaboration agreement to co-develop and co-commercialize long-acting treatment for HIV.
• January 2021 - ViiV Healthcare received USFDA approval for Cabenuva, an injectable drug suggested for treatment of HIV infection.

According to World Health Organization, an estimated 33.0 million people were living with HIV infection and 1.7 million new infected patients were reported in 2019. This massive patient population across the different region increases the demand for antiretroviral (ARV) drugs.

Overview of HIV Drugs:

• Non-nucleoside reverse transcriptase inhibitors (NNRTIs): These drugs block reverse transcriptase, but they do so in a different way than NRTIs. Examples of NNRTIs include efavirenz (EFV), nevirapine (NVP), and etravirine (ETR).
• Protease inhibitors (PIs): These drugs block an enzyme called protease, which is needed by HIV to produce new viruses. Examples of PIs include atazanavir (ATV), darunavir (DRV), and ritonavir (RTV).
• Integrase inhibitors (INIs): These drugs block an enzyme called integrase, which is needed by HIV to integrate its genetic material into the DNA of the host cell. Examples of INIs include raltegravir (RAL), dolutegravir (DTG), and bictegravir (BIC).

Segmentation Analysis:

By Drug:

On the basis of drug class, market can be segmented into combination of medicines, integrase inhibitors, non-nucleoside reverse transcriptase inhibitors (NRTIs) and others. The combination to HIV medicines segment is expected to influence the market. This influence is owing to the increasing demand for this drug class due to better results. According to International AIDS Society (IAS), the integrase inhibitor sector reported for second-largest market share in 2021.Integrase inhibitors is the first method of drug treatment for HIV virus. The non-nucleoside reverse transcriptase inhibitors (NRTIs) report for lowest market share as there is less demand for this drug.

The other segments include protease inhibitors (PIs), fusion inhibitors CCR5 antagonists, post attachment inhibitor, pharmacokinetic enhancer and other drug classes.

• Combination of Medicine
• Integrase Inhibitor
• Non-nucleoside Reverse
• Others 

By Distribution Channel:

Depending on distribution channel, market is segmented into hospital pharmacies, retail pharmacies, online pharmacies and others. The hospital pharmacies segment is estimated to report for largest market share during forecast period. The increasing sales of prescribed antiretroviral drug for HIV infection from hospital pharmacies would support segmental growth. The increasing numbers of retail pharmacies offering HIV medications and high preference to buy oral drugs contribute to segmental growth. The online pharmacies segments would grow at profitable CAGR owing to increase internet penetration and availability of HIV medication.

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Others

Regional Insights:

Geographically, the global HIV Drugs market has been analyzed in different regions like North America, Latin America, Middle East, Asia-Pacific, Africa, Europe, and India. The global HIV Drugs region is dominating this market in the upcoming future.

On the basis of region, the global market can be segmented into North America, Europe, Asia Pacific, and Rest of the World. North America is expected to influence the forecast period, with a market size of USD 20.27 billion by 2020. The influence of the region is attributed to the increasing prevalence of HIV infection among the U.S. population. According to a 2021 study by the Centers for Disease Control (CDC), approximately 1.2 million people were living with HIV at the end of 2018. Such a high patient population base significantly increases the demand for HIV drugs. Another factor contributing to regional growth is population awareness. Moreover, the presence of key players offering innovative HIV drugs for the treatment of HIV infection will further increase the market growth.

Europe is expected to be the second largest market during the forecast period due to increasing HIV infection cases and the presence of a large number of HIV drug companies in the region. Moreover, increasing strategic association among European companies will raise drug availability, which will support market growth in the region. For example, in July 2020, Theratechnologies Inc.'s European subsidiary Theratechnologies Europe Limited partnered with Loxxess to distribute the antiretroviral drug Trogarzo throughout Europe.

The Asia Pacific market is expected to be the fastest growing market with the highest CAGR during the forecast period owing to the high number of HIV patients in densely populated countries like China and India. Moreover, growing number of therapeutic programs and surging funding from the private sector and healthcare companies are expected to drive the market. For example, in December 2020, Gilead Sciences, Inc., one of the leading antiretroviral drug companies, announced a $1.4 million grant for its "Gilead Asia Pacific Rainbow Grant Program" in the Asia Pacific region. 

Rest of the world, including Latin America, Middle East & Africa, is expected to have a lower market share due to lack of technologically advanced HIV medicines, poor healthcare standards, and relatively limited healthcare spending.

• North America
• US
• Canada
• Mexico
• Rest of North America
• Europe
• Germany
• France
• Italy
• Spain
• UK
• Nordic Countries
• Denmark
• Finland
• Iceland
• Sweden
• Norway
• Benelux Union
• Belgium
• The Netherlands
• Luxembourg
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Australia
• South Korea
• Southeast Asia
• Indonesia
• Thailand
• Malaysia
• Singapore
• Rest of Southeast Asia
• Rest of Asia-Pacific
• The Middle East & Africa
• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest of the Middle East & Africa
• Latin America
• Brazil
• Argentina
• Rest of Latin America

Key Vendors:

The competitive landscape for global HIV drug market has the presence of key market players, like ViiV Healthcare, Gilead Science, Janssen Pharmaceutical Inc., and Merck & Dohme Corp. These companies comprise huge proportion of the market. In March 2021, Gilead Science Inc., and Merck & Dohme Corp. entered into an agreement for co-commercialization and co-development of long acting treatment with combination of Islatravir and Lenacapavir for HIV patients. The other prominent player the global market includes Bristol-Myers Squibb Company, Theratechnologies Inc., Viatris (Mylen Pharmaceuticals), Genetech. These companies increase the growth of market share in the forecast period.

• Merck & Dohme Corp. (Kenilworth, France)

Merck & Dohme is the pharmaceutical company which deliver innovative health solutions that advance prevention and treatment of disease in peoples and animals. They create a global workforce that is diverse and inclusive, and act responsibly every day to ensure a secure, sustainable, and healthy future for all people and communities.

• Gilead Science, Inc. (Foster city, USA)

Gilead Sciences is a biopharmaceutical company for infectious diseases, including hepatitis, HIV, and infections related to AIDS. AmBisome, an antifungal agent for the treatment of serious invasive fungal infections caused by a variety of fungal species in adults, and Letairis, an oral formulation of an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension, are two additional products on the market.

• Janssen Pharmaceutical Inc. (Johnson and Johnson, Belgium)

Janssen Pharmaceutical is the pharmaceutical company of Johnson & Johnson working tirelessly to make this future a reality for all patients by combating disease with science, enhancing access with ingenuity, curing hopelessness with compassion, and forming partnerships. Cardiovascular & Metabolism, Immunology, Infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension are the areas of medicine in which we are able to make the greatest impact.

• ViiV Healthcare (Research Triangle Park, U.S)

Viiv Healthcare is a global HIV specialist company with a singular concentration on developing and delivering new medicines and expanding access to care for people living with HIV. Our international headquarters are located in Brentford, London, while our American headquarters are in Research Triangle Park, North Carolina.

• Bristol-Myers Squibb Company (New York city, U.S)

Bristol-Myers Squibb constructed a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to determine how to deliver the right medicine to the right patient at the right moment for the best outcome. The mission is to provide patients with new hope in their fight against life-threatening illness – it drives everything we do.

• Mylan Pharmaceuticals (Canonsburg USA)

Mylan NV is a healthcare pharmaceutical company. The company develops, licenses, manufactures, distributes, and markets generic, branded generic, and specialty pharmaceutical products.

• Genentech (South San Francisco, USA)

Genentech is a biotechnology company committed to advancing science in order to discover and develop medicines for individuals with life-threatening illnesses. Our innovative discoveries include the world's first cancer-targeted antibody and the world's first treatment for primary progressive multiple sclerosis.

• GlaxoSmithKline plc. (Brentford, U.K)

GlaxoSmithKline plc is a pharmaceutical, biological, and healthcare company based in the United Kingdom. GSK is a research-based company with an extensive portfolio of anti-infectives, central nervous system (CNS), respiratory, gastro-intestinal/metabolic, oncology, and vaccines. In addition, it has a Consumer Healthcare division that includes prominent oral healthcare products, nutritional beverages, and over-the-counter (OTC) medications.

Scope of Report:

Conclusion:

• North America reported for 48.40% market share in 2019, and is expected to maintain this trend over the forecast period.
• On the basis of medication class, the multi-class combination drugs segment is anticipated to grow at a CAGR of 4.1% from 2020 to 2027.
• The Asia-Pacific HIV drugs market is estimated to grow at a CAGR of 4.4% during the forecast period.